AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32847542 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid women (general population)
Number of subjects: 938
Study 32847548 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme™ Laryngeal Mask Airway (sLMA) during cesarean delivery with labor
Number of subjects: 584
Study 32847548 — intervention group
Group type: COMPARATOR
Intervention: Supreme™ Laryngeal Mask Airway (sLMA) during cesarean delivery without labor
Number of subjects: 584
Study 32847548 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme™ Laryngeal Mask Airway (sLMA) during cesarean delivery
Number of subjects: 584
Study 32847746 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200mg) every 3 weeks for three cycles
Number of subjects: 1
Study 32847826 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes management during hospitalization for COVID-19
Number of subjects: 0
Study 32847910 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally informed Family Motivational Engagement Strategy (FAMES)
Number of subjects: 200
Study 32847910 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation toolkit
Number of subjects: 200
Study 32847933 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 (1.25 mg/kg every 2 weeks)
Number of subjects: 34
Study 32847933 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 (1.0 mg/kg on weeks 1, 2, 4, and 5)
Number of subjects: 34
Study 32847933 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 (100 mg once weekly)
Number of subjects: 34
Study 32847933 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 (100 mg every 2 weeks)
Number of subjects: 34
Study 32847933 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855
Number of subjects: 34
Study 32847948 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 2011
Study 32847948 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 2011
Study 32847973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib, Bevacizumab, and Paclitaxel (Paclitaxel 80 mg/m2)
Number of subjects: 0
Study 32847973 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 32847993 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 162
Study 32847993 — intervention group
Group type: EXPERIMENTAL
Intervention: Canteen intervention
Number of subjects: 162
Study 32847993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during the first period)
Number of subjects: 162
Study 32848571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40
Study 32848571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32848820 — intervention group
Group type: EXPERIMENTAL
Intervention: ReWin(d) group
Number of subjects: 33
Study 32848820 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 33
Study 32849176 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented telerehabilitation
Number of subjects: 0
Study 32849176 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32849196 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-DRAGON Score
Number of subjects: 0
Study 32849196 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Features Set
Number of subjects: 0
Study 32849209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 32849209 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32849212 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 0
Study 32849212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32849235 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Repetitive Transcranial Magnetic Stimulation (TMS)
Number of subjects: 0
Study 32849281 — intervention group
Group type: EXPERIMENTAL
Intervention: heat-killed yeast-CEA vaccine (NCT01856920)
Number of subjects: 1
Study 32849281 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab (PD-L1 inhibitor, NCT01772004)
Number of subjects: 1
Study 32849667 — intervention group
Group type: EXPERIMENTAL
Intervention: Live viral vaccines (including measles-mumps-rubella - MMR)
Number of subjects: 104
Study 32849914 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) in combination with bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL)
Number of subjects: 0
Study 32849914 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab/oxaliplatin/fluoropyrimidine regimens (mFOLFOX-6/mOXXEL) without VPA
Number of subjects: 0
Study 32850444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0
Study 32850558 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphrasia Eye Drops
Number of subjects: 0
Study 32850558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32850876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Psoralen Plus UV-A (PUVA) Photochemotherapy
Number of subjects: 0
Study 32850921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 32851257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone
Number of subjects: 0
Study 32851257 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0
Study 32851257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32851490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral water ingestion
Number of subjects: 0
Study 32851490 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32851578 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - single radioablation session of 25 Gy
Number of subjects: 15
Study 32851583 — intervention group
Group type: EXPERIMENTAL
Intervention: Geneva cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, fexofenadine)
Number of subjects: 265
Study 32851663 — intervention group
Group type: COMPARATOR
Intervention: Oral antioxidants (including combinations of antioxidants, N-acetylcysteine, melatonin, L-arginine, myo-inositol, carnitine, selenium, vitamin E, vitamin B complex, vitamin C, vitamin D+calcium, CoQ10, omega-3-polyunsaturated fatty acids)
Number of subjects: 7760
Study 32851663 — intervention group
Group type: COMPARATOR
Intervention: Oral antioxidants
Number of subjects: 7760
Study 32851872 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 0
Study 32851872 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study 32851896 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-alert training (SAT)
Number of subjects: 0
Study 32851896 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 0
Study 32851896 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback training (SAT and PMR)
Number of subjects: 0
Study 32852696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 410
Study 32852696 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 410
Study 32852803 — intervention group
Group type: EXPERIMENTAL
Intervention: Home induction with vaginal prostaglandin E (PGE)
Number of subjects: 1610
Study 32852803 — intervention group
Group type: EXPERIMENTAL
Intervention: Home induction with controlled release PGE
Number of subjects: 1610
Study 32852803 — intervention group
Group type: EXPERIMENTAL
Intervention: Home induction with balloon or Foley catheter
Number of subjects: 1610
Study 32853001 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation training delivered by care managers using a registry checklist.
Number of subjects: 455
Study 32853001 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry-based checklist for training and support.
Number of subjects: 455
Study 32853224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food (UPF) intake
Number of subjects: 110260
Study 32853332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0
Study 32853332 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study 32853411 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 68811
Study 32853411 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert Ultra
Number of subjects: 68811
Study 32853599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild illness cohort
Number of subjects: 60
Study 32853599 — intervention group
Group type: COMPARATOR
Intervention: Severe pneumonia cohort
Number of subjects: 60
Study 32853924 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT-MAD (MyTAP™, Airway Management Inc)
Number of subjects: 50
Study 32854206 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-limiting protocol
Number of subjects: 101
Study 32854206 — intervention group
Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 101
Study 32854536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential afatinib followed by osimertinib
Number of subjects: 0
Study 32854536 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32854610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet and moderate-intensity structured exercise intervention
Number of subjects: 37
Study 32854610 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 37
Study 32854663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic high-sensitivity troponin levels determined by repeat measurements (rise or fall-pattern)
Number of subjects: 251
Study 32854663 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin levels, clinical symptoms, electrocardiogram, echocardiogram, and coronary angiogram findings
Number of subjects: 251
Study 32854663 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography early after stroke
Number of subjects: 251
Study 32854663 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at three and twelve months
Number of subjects: 251
Study 32854671 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar M430 activity tracker (AT) worn for 12 months (6 months intervention + 6 months follow-up)
Number of subjects: 16
Study 32854671 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar M430 activity tracker (AT)
Number of subjects: 16
Study 32854691 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative case study involving direct observations, semi-structured interviews, and artifact collection at six NCCN and NCI Comprehensive Cancer Centers.
Number of subjects: 6
Study 32854691 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with cancer center administrators, providers from various oncology specialties, and patients near end-of-life.
Number of subjects: 6
Study 32854691 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Dedoose software for qualitative data management and analysis.
Number of subjects: 6
Study 32854836 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR) with contemporary devices (n = 740 with Sapien 3; n = 188 with Evolut R/Pro; n = 106 with others)
Number of subjects: 1034
Study 32854836 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR) with calcified raphe and excess leaflet calcification
Number of subjects: 1034
Study 32854836 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR) with both calcified raphe and excess leaflet calcification
Number of subjects: 1034
Study 32855096 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 220
Study 32855096 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study 32856068 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg twice daily
Number of subjects: 6
Study 32856153 — intervention group
Group type: EXPERIMENTAL
Intervention: FLER analysis and visualization using indocyanine green (0.2 mg/kg)
Number of subjects: 22
Study 32856153 — intervention group
Group type: EXPERIMENTAL
Intervention: FLER values
Number of subjects: 22
Study 32856153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactates at proximal resection site
Number of subjects: 22
Study 32856153 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR
Number of subjects: 22
Study 32856226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 104
Study 32856281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampreloxetine (2-50 mg, once-daily oral)
Number of subjects: 0
Study 32856281 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 0
Study 32856497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lancing devices set at maximum depth (5)
Number of subjects: 90
Study 32856497 — intervention group
Group type: COMPARATOR
Intervention: Lancing devices set at minimum depth (1)
Number of subjects: 90
Study 32856597 — intervention group
Group type: EXPERIMENTAL
Intervention: Onduo VDC
Number of subjects: 55
Study 32856945 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Freezing
Number of subjects: 0
Study 32856945 — intervention group
Group type: EXPERIMENTAL
Intervention: Holder Pasteurization
Number of subjects: 0
Study 32856945 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 32857106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Number of subjects: 34
Study 32857114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Number of subjects: 70
Study 32857114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal Condition (Cochlear Implant + Hearing Aid)
Number of subjects: 70
Study 32857114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal Condition
Number of subjects: 70
Study 32857114 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Condition
Number of subjects: 70
Study 32857176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of aromatic amino acids (AAA)
Number of subjects: 112
Study 32857176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of branched-chain amino acids (BCAA)
Number of subjects: 112
Study 32857176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of sulfur amino acids (SAA)
Number of subjects: 112
Study 32857176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of specific amino acids
Number of subjects: 112
Study 32857268 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 7000
Study 32857268 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 7000
Study 32857293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 766
Study 32857293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 766
Study 32857293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 766
Study 32857327 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol SMI
Number of subjects: 9180
Study 32857590 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy, details on dosage and duration not specified.
Number of subjects: 0
Study 32857590 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified),
Number of subjects: 0
Study 32858352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep bruxism (SB) self-report and polysomnography (PSG) assessment
Number of subjects: 1042
Study 32858352 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia syndrome
Number of subjects: 1042
Study 32858352 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea/hypopnea index (AHI) above 30
Number of subjects: 1042
Study 32858352 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male, overweight, or obese
Number of subjects: 1042
Study 32858478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to chemotherapy
Number of subjects: 132
Study 32858478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to anthracycline
Number of subjects: 132
Study 32858531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin in oxytocin-desensitized myometrium
Number of subjects: 17
Study 32858531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin in oxytocin-naïve myometrium
Number of subjects: 17
Study 32858531 — intervention group
Group type: COMPARATOR
Intervention: No nitroglycerin in oxytocin-naïve myometrium
Number of subjects: 17
Study 32858531 — intervention group
Group type: COMPARATOR
Intervention: No nitroglycerin in oxytocin-desensitized myometrium
Number of subjects: 17
Study 32858583 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 20
Study 32858582 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound (US) treatment
Number of subjects: 99
Study 32858584 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdural puncture headache
Number of subjects: 132
Study 32858584 — intervention group
Group type: COMPARATOR
Intervention: Control (uneventful labour epidurals)
Number of subjects: 132
Study 32858752 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring (FGM)
Number of subjects: 111
Study 32859321 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 229
Study 32859321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil intake
Number of subjects: 229
Study 32860168 — intervention group
Group type: EXPERIMENTAL
Intervention: Poziotinib treatment
Number of subjects: 106
Study 32860184 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 1644
Study 32860184 — intervention group
Group type: COMPARATOR
Intervention: Control (no terlipressin)
Number of subjects: 1644
Study 32860424 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines and Z-drugs (BZD/Z)
Number of subjects: 1024
Study 32860500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-induced deep sedation (MOAA/S = 0)
Number of subjects: 30
Study 32860500 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (random forest)
Number of subjects: 30
Study 32860500 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG spectral features (delta, theta, beta bands)
Number of subjects: 30
Study 32860553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle NIBP measurement
Number of subjects: 97
Study 32860956 — intervention group
Group type: EXPERIMENTAL
Intervention: MVR (Multivisceral resection)
Number of subjects: 435
Study 32860956 — intervention group
Group type: COMPARATOR
Intervention: DP without MVR (Control)
Number of subjects: 435
Study 32860956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic fistula rates
Number of subjects: 435
Study 32861651 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D mechanical wave velocity mapping technique
Number of subjects: 15
Study 32861656 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA-derived fractional flow reserve (FFR)
Number of subjects: 4737
Study 32861656 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA and FFR
Number of subjects: 4737
Study 32862518 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) in HFrEF
Number of subjects: 5391
Study 32862518 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ) in HFpEF
Number of subjects: 5391
Study 32862518 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical independence summary score in HFpEF
Number of subjects: 5391
Study 32862518 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ clinical summary score in both HF groups
Number of subjects: 5391
Study 32862715 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffolds loaded with autologous bone marrow mononuclear cells (BMMCs) implanted into the cleaned site
Number of subjects: 7
Study 32863013 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic testing for aneuploidy (PGT-A) assay
Number of subjects: 402
Study 32863013 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophectoderm biopsy
Number of subjects: 402
Study 32863013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biopsy)
Number of subjects: 402
Study 32863016 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion with 250 ml of saline 0.9% over 10 min
Number of subjects: 109
Study 32863171 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 58
Study 32863171 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 58
Study 32863279 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive evaluation of multiterritorial artery stenosis and plaque using advanced vascular imaging techniques
Number of subjects: 3067
Study 32863279 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI and CT angiography
Number of subjects: 3067
Study 32863279 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective collection of cardiovascular/cerebrovascular events and cognitive assessments
Number of subjects: 3067
Study 32863279 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and urine samples for biomarker testing
Number of subjects: 3067
Study 32863639 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedative weaning
Number of subjects: 30
Study 32863639 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 32863882 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Resistance Training (RT)
Number of subjects: 50
Study 32863882 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 50
Study 32864144 — intervention group
Group type: EXPERIMENTAL
Intervention: Local PBMT-sMF
Number of subjects: 30
Study 32864144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32864144 — intervention group
Group type: COMPARATOR
Intervention: Non-local PBMT-sMF
Number of subjects: 30
Study 32864392 — intervention group
Group type: EXPERIMENTAL
Intervention: LSTM (Long Short-Term Memory) recurrent neural network
Number of subjects: 2